Click above to follow us on Stellar Biotech!

The 2025 Asia-Pacific Health & Life Sciences Summit, organized by ASK Health Asia, was successfully held on 20–21 November 2025 at the Singapore Exchange (SGX). Under the theme “Together for Impact: Advancing Healthcare Access, Innovation and Investment in the Asia-Pacific”, the summit brought together leaders from governments, international organizations, academia, industry and investment institutions across the Asia-Pacific and globally. Participants engaged in in-depth discussions on five key pillars: Access, Innovation, Investment, Digital Intelligence, and Climate Resilience.

As a representative innovator in the life sciences sector, Stellar Biotech was invited to attend the summit. Mr. Wildman Liu Weimin, Vice President of Stellar Biotech, shared the company’s cutting-edge practices in the Innovation Showcase session, exploring new industry opportunities with global peers and demonstrating the unique value of Chinese innovation on the international stage.

During the summit’s featured Innovation Showcase, Mr. Wildman Liu Weimin, Vice President of Stellar Biotech, presented the company’s innovative practices and landmark achievements in life sciences and healthcare to a global audience.

As a leading enterprise focused on life sciences innovation, Stellar Biotech takes technological innovation as its core driver, addressing unmet medical needs with a focused approach in oncology, rare diseases, advanced diagnostics and other high-potential segments. The showcased innovations highlighted Stellar Biotech’s strong capabilities in R&D, product translation, and cross-regional resource integration, while embodying the company’s mission to improve healthcare access and advance health equity.

Throughout the session, numerous delegates engaged in in-depth dialogues with the Stellar Biotech team on technology applications, industrial cooperation models and regional market strategies, laying a solid foundation for future collaboration. Stellar Biotech’s innovative practices align closely with the summit’s mission of advancing healthcare innovation in the Asia-Pacific, further strengthening the company’s influence in the regional life sciences ecosystem and building a key bridge for global innovation and international cooperation.

As a top-tier industry event successfully hosted for three consecutive years, the summit established a high-level cross-sector cooperation platform. In his opening remarks, Professor Weiyang CHEONG, Vice Provost for Strategic Research Collaboration at Singapore Management University and Senior Advisor for Health Economics at Singapore’s Ministry of Health, emphasized that with rapid aging in Asian cities, future health systems must be built around the trinity of Prevention – Precision – Population Health. Innovative and value-based care will be central to improving population health and economic resilience.

The summit featured five core thematic tracks, delivered through opening addresses, keynote speeches, panel discussions and innovation showcases, covering critical issues in healthcare: from the paradigm shift of “Health as an Investment”, to R&D innovation and regulatory alignment in regional cooperation; from life sciences investment trends, to the transformation of healthcare systems enabled by AI and digital technologies; and to the sustainable development of healthcare systems under climate resilience. These practical and in-depth exchanges provided valuable insights and references for the development of the Asia-Pacific health industry.

Stellar Biotech, with its deep focus on life sciences innovation, actively embraced the summit’s vision of “innovation-driven, win-win cooperation”, using the platform to exchange cutting-edge technologies and expand partnerships with global industry peers.

Through participation in summit discussions, Stellar Biotech identified three defining trends in the Asia-Pacific health and life sciences sector:

First, value-based healthcare has become an industry consensus. Healthcare is widely viewed as a strategic investment rather than a cost center. Preventive care, precision health, AI applications and public-private partnerships are regarded as key to improving health outcomes and economic returns — a vision fully aligned with Stellar Biotech’s focus on precision medicine and creating clinical value through innovation.

Second, regional collaboration and innovation integration are accelerating. Cross-regional cooperation in R&D, regulatory alignment, and clinical partnerships is increasingly urgent across the Asia-Pacific. Trust-building, shared standards, and coordinated regional frameworks will meaningfully accelerate access to advanced therapies. Stellar Biotech will actively integrate into the regional innovation ecosystem and enhance technology translation efficiency through cross-border collaboration.

Third, technological innovation and sustainable development go hand in hand. The deep integration of AI, digital technologies, and life sciences, together with the building of low-carbon and climate-resilient healthcare systems, represent critical future directions. Stellar Biotech will continue to pursue both technological innovation and sustainable development, supporting the creation of a green and resilient healthcare ecosystem.

The successful 2025 Asia-Pacific Health & Life Sciences Summit has delivered strong momentum for collaborative development in the regional healthcare industry. Through this summit, Stellar Biotech gained cutting-edge industry insights, expanded its global partnership network, and strengthened its commitment to empowering healthcare through innovative technologies.

Moving forward, Stellar Biotech will continue to deepen its focus on life sciences, prioritize core R&D and product translation, and proactively align with industry trends and the Asia-Pacific regional innovation cooperation ecosystem. Guided by a patient-centric philosophy, the company will deliver more innovative solutions to enhance healthcare access and service quality, contributing to the sustainable development of the Asia-Pacific health industry and the goal of sustainable, accessible, and equitable healthcare for all.

Stellar Biotech extends its sincere gratitude to the 2025 Asia-Pacific Health & Life Sciences Summit for providing this high-level platform. We look forward to partnering with more industry peers to advance health and life sciences, and co-create a brighter future for healthcare in the Asia-Pacific.

Stellar Biotech is an innovative pharmaceutical and medical device service company dedicated to the cross-border introduction, R&D, manufacturing and commercialization of global pharmaceuticals and medical devices. The company specializes in accelerated market access for global pharma and medtech enterprises, providing end-to-end services for innovative drugs, traditional Chinese medicines and advanced medical devices — including regulatory registration, licensing, early market access, drug distribution, and marketing promotion — across Southeast Asia (including Hong Kong and Macau), helping patients gain faster access to world-class advanced medical resources.

Backed by more than 30 medical KOLs and experts, Stellar Biotech currently has over 10 commercialization projects underway covering innovative drugs, proprietary Chinese medicines and medical devices, with an expected total product market scale exceeding ¥5 billion.

This version is polished, formal, and ready for direct use on your official website, PPTs, press releases, and global marketing materials.

Released on December 5th, 2025